Lunit KRX:328130KOSDAQ
루닛 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days49
DART filings, 7 days0
Articles tracked222since Sep 11
In Q2 2026, Lunit reported revenue of ₩21.8bn, up 22.0% year on year, and an operating loss of ₩15.4bn. Lunit (루닛) appeared in 49 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 33 articles. The most common catalyst was tech & capacity (8). It was most often mentioned alongside Vuno, 글로벌테크놀로지 and Seers.
Filing signals 4 quarters of losses Screener
Lunit quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩21.8bn | +22.0% | −₩15.4bn margin −70.5% | −₩23.6bn |
| Q1 2026 | ₩24.0bn | +24.7% | −₩13.6bn margin −56.8% | −₩17.8bn |
| Q4 2025 derived | ₩26.5bn | +32.1% | −₩19.6bn margin −74.2% | −₩32.4bn |
| Q3 2025 | ₩19.6bn | +16.7% | −₩21.6bn margin −110.1% | ₩18.1bn |
| Q2 2025 | ₩17.9bn | +46.2% | −₩21.1bn margin −118.1% | −₩35.0bn |
| Q1 2025 | ₩19.2bn | +273.6% | −₩20.7bn margin −107.6% | ₩2.0bn |
| Q4 2024 derived | ₩20.0bn | +271.3% | −₩18.5bn margin −92.3% | −₩73.4bn |
| Q3 2024 | ₩16.8bn | +413.3% | −₩16.4bn margin −98.0% | −₩11.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Lunit top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Lunit news Korean headlines
-
[ESMO 2026]임유주 루닛 메디컬디렉터 “AI로 암종별 데이터 발굴...신약개발까지 확장”
1 more on this story · 1 outlets
- [ESMO 2026]임유주 루닛 메디컬디렉터 “AI로 암종별 데이터 발굴...신약개발까지 확장”이데일리 · Oct 28 07:06
-
루닛이 끌어올린 의료AI…뷰노 평가·뉴로핏 빅파마 계약 주목[바이오맥짚기]
1 more on this story · 1 outlets
- 루닛이 끌어올린 의료AI…뷰노 평가·뉴로핏 빅파마 계약 주목[바이오맥짚기]이데일리 · Oct 28 07:01
-
[적중! 대박 예감] '루닛, 토마토시스템, HD건설기계' 내일장 예감 좋은 대박 종목?
1 more on this story · 1 outlets
- [적중! 대박 예감] '루닛, 토마토시스템, HD건설기계' 내일장 예감 좋은 대박 종목?머니투데이 · Oct 27 07:01
-
Featured루닛, '美 바이오기업과 협업'에 장 초반 강세
1 more on this story · 1 outlets
- [ET특징주]루닛, '美 바이오기업과 협업'에 상승세전자신문 · Oct 26 13:26
-
Featured루닛, 美 바이오 기업과 협력·재평가 전망에 26%대 급등
1 more on this story · 1 outlets
- 루닛, 美 바이오 기업과 협력·재평가 전망에 26%대 급등조선일보 · Oct 26 09:38
-
루닛, 장 중 상한가…美 항암제 개발 협력·재평가 기대감 영향
1 more on this story · 1 outlets
- [핫타임] 루닛, 美 서밋과 항암제 개발 협력·재평가 전망에 상한가아주경제 · Oct 26 09:45
-
루닛, 美 서밋과 항암 신약 개발 협력에 급등
1 more on this story · 1 outlets
- 루닛, 미국 서밋과 항암 신약 개발 협력…장초반 ‘상한가’매일경제 · Oct 26 11:06